InnoCare Pharma Limited
9969)
377,549245,958131,26599,292(191,208)(186,054)(358,130)(273,519)
(87,299)(78,519)(179,150)(160,544)(429,184)(445,812) (206,261)(225,020)
(429,184)(445,812)178,005155,042
44,91865,750(206,261)(225,020)
246.0
53.5%377.5
217.047.8%
320.7
99.3
131.3
59.2
34.693.8
698.6
815.8
(i)
273.5358.1(ii)
264.6278.5(iii)
155.0178.0
445.8429.2
225.0206.3
8,688.66,518.89,011.2
TafasitamabICP-248ICP-B02ICP-490NHL
MM
BDLBCL
?
?BTK320.7
217.047.8%
CSCO
? MZLNDA
NMPA
MZLBTKIRCORR58.9%DOR34.3
(95% CI)12PFSOS82.8%91%? CLL/SLL
IIINDA
? MCLII
FDAFDANDA? MCDDLBCLIII
R-CHOP
R-CHOPMCDDLBCL
ICP-B04TafasitamabCD19Minjuvi
?? BDLBCL
II
CDENDA
NDATafasitamabDLBCL
TafasitamabBLAASCTDLBCL
DLBCL? TafasitamabDLBCL
ASCT
DLBCLTafasitamabCSCOASCTDLBCL
ICP-248? ICP-248B2BCL-2
ICLL/SLLMCLNHL
BCL-2PKCRuMRD
CLL/SLL
IND
ICP-B02 (CM355)? CP-B02CD20xCD3I/II
ICP-B02NHLPKIVSC
IVSCICP-B02FLDLBCL
ICP-490? ICP-490
MMI
1DLT21CD3+TBPD
Aiolos (IKZF3)Ikaro (IKZF1)
TICP-490MM
ICP-B05 (CM369)? ICP-B05C-C8CCR8
(2162.HK)
IICP-B05
DLTPKPDT
NHLIND
BTBT
?
ITPPoCITPIIPoCEHA
50QD40%GC
IVIGBTKITPAIDBTK? SLEIIaSLE
SRI-4
IIb
? MSII24
Cmax
50QD80QD24Gd+T1
92.3%MS
4T12480QDGd+T124TEAEMSICP-332? ICP-3322TYK2T
IPK
JAK-2AEAD80120QDII
II
ICP-488? ICP-488TYK2TYK2
JH2IL-23IL12IIFN
ICP-488I
SADMADPoCI
2II
PoC
ICP-192ICP-723ICP-189ICP-B05ICP-033
ICP-723 (Zurletrectinib)? I/IIICP-723
NTRKTRKiPK
ICP-723NTRK12
II
ORR80%-90%ZurletrectinibTRKTRKiCDE212INDICP-192 (Gunagratinib)
? Gunagratinib
FGFR
ICCAIIASCO-GIGunagratinibIIa
ICP-192
ICP-189
? ICP-189SHP2
IaICP-189
120QDDLTPKICP-189
201PRICP-189ArriVentfurmonertinibEGFRINDArriVent
ArriVent BiopharmaArriVent
SHP2ICP-189ArriVentfurmonertinibEGFR
ArriVentICP-189furmonertinibNSCLC
ICP-189furmonertinibINDCDE
Tafasitamab
NDA
PH3PHIaPH2*
NDA
PHIbPH2**
ICP-022/Orelabrutinib
BTK
r/rCLL/SLL20201225
r/rMCL20201225
r/rMZL2023421
ICP-B02CD3xCD20
ICP-248NHL/ALL/BCL-2
ICP-490MM/DLBCL/E3 Ligase
1L : CLL/SLL
Tafa + LEN, r/rDLBCLr/rMCL1L : MCL
ICP-B04/
Tafasitamab
CD19
IV&SC
1L : MCD DLBCL
HK
CHN,S
CHN
CCR8ICP-B05
CHN
2024
20242024
NDA
PH3PHIaPH2*PHIbPH2**
ICP-B05
pan-FGFR
()pan-TRKNTRK
()ICP-192/GunagratinibICP-723/Zurletrectinib
VEGFR,DDR1ICP-033
SHP2ICP-189
CCR8
20232
IIPoC
BTK
TYK2 –JH1
ICP-022/OrelabrutinibICP-332
TYK2 –JH2
/
ICP-488
+EGFRiNSCLCIND
?BTK
?BTK
CLL/SLLMCL
?
CSCOCLL/SLLMCLBTKDLBCLpCNSL
377.5
320.7
47.8%330
DOT
TafasitamabICP-248ICP-B02ICP-490
NHLMM
BDLBCL
NHLNM(i)(ii)FDAEMACD19TafasitamabDLBCL(iii)
BCL-2CD20xCD3E3CCR8(iv)DLBCLTafasitamabBCL-2E3
DLBCL1L DLBCLMCDTafasitamab
DLBCL
MMOthersCLL/SLLMCLMZLWMFLCNSLDLBCL
PTCL/CTCL
AMLALLCMLOthers
ICP-490
ICP-B02
Orelabrutinib
ICP-490
ICP-248
ICP-B05/CM369
TafasitamabICP-248
850CLL/SLLMCL
MZLBTKAE3
MZLMZLBNHL
8.3%MZL
MZL
NMPAMZL
MZLBTK
ICML
MZLIRCORR
IV75.9%24.3IRCORR58.9%DoR
34.3PFS12PFS82.8%12OS91%
TRAE12
MCLMCLBBMCL60
MCL
CRBloodBlood Advances
BTKMCLMCL10646.98CT
ORR83%35.8%CR3.8%CRu43.4%PR
25.7924.94OS56.21MCLII
FDABTDMCL1L CLL/SLL
IIICLL/SLL
IRCPFS
III531L CLL
NDA1L DLBCL-MCD
DLBCLNHL100
MCD1L DLBCL
IIIR-CHOPR-CHOPMCDDLBCL
40%DLBCL
R-CHOP+XMCDBNF-KBBTK
TITKCD20NKADCC
R-CHOPMCDDLBCL
ASCOR-CHOPMCD DLBCL14MCD DLBCL
1508R-CHOPR-EPOCH6RICER-CHOPR2CRR75%66.67%
MCDDLBCL
MCDDLBCL
CLL/SLLIICLL/SLL15080CLL/SLL
52.442.5%
ORR93.8%CR30%1.84DORPFS5250
CLL/SLLBTKCRAE
CLL/SLLGazyvaFCR
BTKi
7.1611.073PR/PR-LSDORR75%DCR100%
BTKiCLL/CLL
1L DLBCLGCB
EHA
ORIENTR-CHOP
BBGCB DLBCL
R-CHOPGCB DLBCL
GCB DLBCLR-CHOPTafasitamab (CD19)ICP-B02 (CD3xCD20)ICP-490E3DLBCL
pCNSLEHAPomalidomide
MethotrexateCNSII
pCNSLND pCNSLPomalidomideORR
pCNSLpCNSLND pCNSLCNSLpCNSLORRCR88.9%100%53.9%61.8%ND pCNSL
PFSmPFS6PFS63.6%100%
60%CNSLORR60%
86.7%mPFS9.83
mPFSBCRMYD88MOABBB
15021.6BBB
58.6%
pCNSL
BTKCD20
BTKBBCRCD20CDCADCC/ADCPBTK2TTKL
NKADCC
(Mol Ther Oncolytics 21: 158-1702021
BTKBTKITK
B
ADCC
Mol Ther Oncolytics 21:158-1702021GazyvaADCCADCP
CD20Gazyva (obinutuzumab)ADCCADCP
BTK
CD20/CD19B
CD20GazyvaBTafasitamabNHLIIICP-B04 (Tafasitamab)
CSCOTafasitamabASCTDLBCL
DLBCLCHOP
Tafasitamab23
TafasitamabDLBCLTafasitamab
TafasitamabDLBCLII
IITafasitamabDLBCL
ORRIRCDCRDoRPFSTTPTTROS
NDATafasitamabFDA
DLBCLDLBCLASCTIIL-MINDORR(40% CR)57.5%(mOS)33.543.9mDoRTafasitamabCD19
B-NHLB-NHLRE-MIND2R2Tafasitamab
TafasitamabTafasitamabTafasitamabTafasitamabNMPA
2CRTafasitamabBLAASCT
DLBCLDLBCL
TafasitamabBDLBCLNHLNHL40%
NHL/DLBCLTafasitamab
ICP-248
ICP-248B2BCL-2BCL-2BCL-2
BCL-2ICP-248ICP-248BCL-2ICP-248CLL/SLLNHLDLBCL
II
ICP-248BCLL/SLLMCLNHLBCL-2CRSDCLL/SLL
NDAICP-B02 (CM355)ICP-B02B
CD20xCD3TDCCI/IIICP-B02IVSCNHLPK
IICP-B025IV1SCDLT1SCDLTIVSCNHLDLBCLIV
SCICP-490ICP-490CRBN E3
IMiDTPD
CRL4CRBN-E3ICP-490IKZF1IkarosIKZF3AiolosICP-490MMB
DLBCLICP-490
CRNBICP-490ADCCCD38daratumumab
AACRICP-490ICP-490MMNHLDLBCL
IC50ICP-490
ICP-490ICP-490MMDLBCLICP-490
ICP-490IL-2BCD38daratumumabMMNHLICP-490BTKICP-490MMI2
1CD3+ TBAiolos (IKZF3)Ikaro (IKZF1)
TICP-490ICP-490IberdomideCRBNICP-490MMNHLICP-B05 (CM369)ICP-B05C-C8CCR8CCR8TMETTregsICP-B05CCR8TregsADCC
TregsTMEICP-B05T
IICP-B05DLTPKIICP-B05
CCR8TICP-B05NHLICP-B05NHLIND
BTBT
ICP-332 (TYK2-JH1)ICP-488 (TYK2-JH2)
ADPsoriasis
LN
CD
UC
SLE
MSITPNMOSDCSU
T
B
(BTK)
I/II
II
IIaIIb
II
IIIIPoCIIIMSNMOSDITPCSUSLEADLNCD
CNSB
ITPPoCGCIVIGIIISLEIIaSLEBTKIIbMSIIPoCIINMOSDCSU
TTYK2ICP-332ICP-488TADSLELNCDUC
BICP-332ICP-488T
BBTKTECB
BCRBBTKBTK
ITPITPITP
TITP100,00023.6100,000
9.5
CD20
BTKBITPB
BTKITPITP
ITPIIIIITP
III
×
/L2
ITPPoCEHA
ITPII
3350QD30QDITP50QDGCIVIG
36.4%33125040%1561283.3%121014-2464
50x10
/L22GCIVIG50
75.0%86ITPTRAE12IIITP
BTKITP
BTKAID
SLEBTKBCRBSLE
SLE
SLE1.06
0.7%SLE1.09
0.5%
SLEIIaEULAR
SLE1:1:1:11250QD80QD100QDIIa
508010012SRI-4
35.7%50.0%61.5%64.3%
GC3C4
35.7%
50.0%
61.5%
64.3%
14.3%
25.8%
28.6%
(n=55)
0%10%20%30%40%50%60%70%80%90%
| 100% |
(N=14)
(N=14)
(N=13)
(N=14)
IIa40IIb
IIbSLESLESLE
1:1:1507548SRI-4SRI-4
C3C4dsNDA4850%
SLEBTKevobrutinibfenebrutinib
Ringheim, G. E., Wampole, M., & Oberoi, K. (2021) Frontiers in Immunology, 12,662223SLEBTKSLE
MS
ICP-CL-00112IIRMS
24OLEII
MSII2412
Cmax4T1241250QD80QD24Gd+T192.3%MS
24Gd+T1PHSN=115
4812162024
50QD50QD
| BID |
80QD
50QD
QD=BID=CI=Gd+ =424Gd+T1
50QD(N=27)
50QD
(N=30)
50BID(N=29)
80QD(N=29)
(95% CI)
6.45 (3.62, 11.52)2.10 (0.62, 7.11)1.08 (0.30, 3.81)0.50 (0.09, 2.74)
(-22.0, 91.3)83.3 67.4 (33.2, 95.8)92.3 (56.5, 98.6)
0.09580.0114
0.0037
P
80QDGd+T124
TEAEMSALT/AST>8xULN50BID50QD80QDFDA
MSDMTFDA
Biolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M, Grieco A. TheDisease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and LiverInjury: A Narrative Review. CNS Drugs . 2021 Aug;35(8):861-880
26MS2624
HBV
DMTBiolato M, Bianco A, LucchiniM, Gasbarrini A, Mirabella M, Grieco A. The Disease-Modifying Therapies ofRelapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. CNSDrugs. 2021 Aug;35(8):861-880
ALT
ALT
ALTβ136
136912C
62C
BC
A
BMSIIMSOLE
MSBTK
NMOSDNMOSD
45-650.445/100,000
4.71:1
BTKBBBTKBTKBTK
NMOSD
IITIITTYK2ICP-332ICP-332TYK2TYK2JAKIL-12/IL-23
IFNT17TH17TH1BADICP-332TYK2
400JAK2JAK
TYK2ICP-332
IBDPharma Intelligence
120.96-22.6%1.2-17.1%
ICP-332
IPK/PDJAK-2AE
ADIIII
I14ICP-332532040160QDPKPD8ICP-3326280ICP-322
ICP-3325320PKCmaxAUC last
IMAD
14320160QDICP-332
JAK2
II
ICP-488ICP-488TYK2JH2JH2TYK2
JH2TYK2ICP-488TYK2TYK2 JH2IL-23IL-12IIFNICP-488SLELNIBDICP-332ICP-488
TYK2I
136SADMAD2
IIICP-488IIJAKICP-488
ICP-192ICP-723
ICP-189furmonertinibsNSCLC
ICP-B05ICP-033
ICP-723 (Zurletrectinib)
ICP-192 (Gunagratinib)
RTKiMEKi
EGFRiCDK4/6i
VEGFiPD-1/PD-L 1
KRASi
ICIRAFi
ICP-189
SHP-2
ICP-B05CCR8
NTRK8ORR80%90%
ORR 52.9%DCR 94.1%
FGFRICP-192TRKICP-723
SHP2CCR8ICP-189ICP-B05ICP-
ICP-723 (Zurletrectinib)ICP-723TRK
TRKTRKNTRKTRKTRKICP-723TRKA/B/CTRKAG595RG667CICP-723TRK
TRKTRKATRKBTRKC
NTRK1NTRK2NTRK3TRK
NTRKNTRKNTRK
NTRK1218ICP-723CDE212IND
ICP-723NTRK12II
ORR80%-90%ZurletrectinibTRKTRKiICP-192 (Gunagratinib)Gunagratinib
FGFRFGFR
7.1%
GunagratinibFGFR
FGFRGunagratinibFGFR
GunagratinibCCAIIaICP-19218CCA17
5.57ORR52.9%17
9DCR94.1%1716mPFS
6.9395% CI5.42TRAE
FGFRGunagratinibCCAFGR2
(52.9%)II
ICP-192ICP-189ICP-189SHP2ICP-189SHP2RAS-MAPK
PD-1SHP2
ICP-189ICP-189EGFRKRASMEKPD-1ICP-189ICP-189p-ERKDUSP6 mRNA
IaICP-189120DLT3TRAESAEICP-189
PRICP-189PKICP-189
EGFRPD-1IbCDEICP-189EGFRiIND
ICP-189INDFDAIArriVent
ArriVent BiopharmaArriVentSHP2ICP-189ArriVentfurmonertinib
EGFRArriVentICP-189furmonertinibNSCLCNSCLC85%ArriVentEGFRHER220NSCLC
furmonertinibEGFR1919DEL21(L858R)NSCLC
furmonertinibAllist Pharmaceuticals
FurmonertinibICP-189
ICP-033
ICP-0331DDR1
VEGFR
ICP-033ICP-033
ICP-033I
PROTACXDC
50,000GMP
NMPABTK
30,000
CMC
70,381
8.05(3)
18A.0918A.11B
3.10(1)
3.11
ICP-248ICP-B02TafasitamabICP-490
MMNHLMZL
?BCLL/SLLMCLMCDDLBCL
MCLNHLBT
BITPIIPoCSLEIIaSLE
BTKIIb
NMOSDIICSUMultiple Sclerosis International FederationMSIF280MSFrost & Sullivan
MS230317BTKBMSBTK
MSMS
TICP-332ICP-488
TADSLELNIBDBICP-332ICP-488T
ICP-192ICP-723ICP-189ICP-B05ICP-033
IND
ICP-B02ICP-B05Tafasitamab
%%321,46685.1217,07188.356,08314.928,88711.7377,549100.0245,958100.0
246.0
377.5
104.448.1%
321.5
28.927.294.1%
56.1
%%279,33392.7179,75598.122,1447.33,4651.9301,477100.0183,220100.0
183.2
74.5%
301.579.9%
99.3
131.3
59.2
34.693.8
273.5
358.1
%%146,56140.992,93534.0117,65432.998,89936.220,8085.829,74610.928,2067.918,1776.644,90112.533,76212.3358,130100.0273,519100.0
(i) 92.953.7146.6
(ii) 98.918.8117.7(iii) 29.78.920.8(iv) 18.210.028.2(v) 33.811.1
44.9
78.5
87.3(i)
34.839.8(ii)
4.3
7.1(iii)2.1
4.2(iv)7.4
11.3
%%39,77245.634,79644.313,56815.517,34022.111,35113.012,66816.17,1178.24,2725.44,2264.82,0532.611,26512.97,3909.587,299100.078,519100.0
186.1
191.2
(i)68.4
81.3(ii)16.8
23.1
%%
76,28739.982,12044.181,28142.568,43736.810,5425.518,66410.023,09812.116,8339.1191,208100.0186,054100.0
160.5179.2
19.4
23.7
2.1
8.8
1.4
20.3
209,269127,825104,01395,344109,48365,322321,580313,2908,367,0678,697,9279,111,4129,299,708
5,000–129,429118,597
–4,242687,566727,552
10,8857,75719,42420,1121,220,8751,197,1682,073,1792,075,4287,038,2337,224,2807,038.28,367.1
209.3104.0
109.5321.6
129.4687.61,220.9
192,065127,82217,2043209,269127,825
95.3104.0(i)33.6
3.437.0(ii)
45.06.8
51.8
36,96933,55751,81144,9877,73512,1477,4984,653104,01395,344
65.3
109.5
321.6
313.3
121,589111,1867,7897,3354266
129,429118,597
727.6
687.6(i)
104.1
98.9(ii)
57.0
41.7(iii)
32.621.3(iv)
51.4
30.8
98,922104,05041,73457,01421,32032,5808,0547,62830,75051,391470,981459,51715,80515,372687,566727,552
5,000–19,42420,112470,981459,5171,220,8751,197,168
7,700–35,16535,439296,451287,7612,055,5961,999,997
2,000.02,055.6
286.0
286.6
653.2
715.8
284.1
279.3
41.3
38.6
11.7
9.6
28.0
32.8
4.44.5
8,697.98,367.165.3109.5
127.8209.3
8.95
250,324,0000.0000023,8832,240.4
H.10
37,548,00015%
322.59
210,508,00014.45
264,648,2170.000002
11.03
2,778.82
8,688.69,011.2
(i)(ii)8.3
300.0
100%19.6%
18.8%
1,220.9
296.5
12.7
471.0
158.5
400.012.7
387.3
–
–
(i)(ii)
(iii)
13.51B(1)
C.2.1
(i)(ii)
(iii)
3.10(2)3.21
2,415.671,390.657.6%
50%1,207,835411,99887,447324,551
40%*966,268696,20138,285657,916
10%241,56747,3164,72542,591
2,415,6701,155,515130,4571,025,058
*
(i)(ii)
Gaoling Fund L.P.YHG Investment L.P.Vivo Opportunity Fund, L.P.210,508,000
16.33%14.04%
14.45421.023,041.44210,508,000
14.45
15.723,041.843,041.44
3,041,4401,848,6981,192,742
2,919.07140.25
2,778.82
1,494,220.6221,902.91,272,317.7
116,146.682,980.733,165.9
273,851.493,790.0180,061.4
60,952.318,957.941,994.4
833,644.7277,089.3556,555.4
2,778,815.6694,720.82,084,094.8
377,549245,958(76,072)(62,738)301,477183,220
131,26599,292(191,208)(186,054)(358,130)(273,519)(87,299)(78,519)(179,150)(160,544)(23,707)(19,406)
–(85)(2,087)(8,800)
(20,345)(1,397)(429,184)(445,812)
––
(429,184)(445,812)
(422,211)(441,343)
(6,973)(4,469)(429,184)(445,812)
(0.25)(0.31)
(429,184)(445,812)
233,692238,653233,692238,653(195,492)(207,159)
(188,519)(202,690)
(6,973)(4,469)(195,492)(207,159)
715,809653,163279,278284,1033,1253,12538,63641,3059,62511,71232,83128,0421,079,3041,021,450
109,48365,322
209,269127,825
104,01395,344321,580313,2908,367,0678,697,9279,111,4129,299,708
129,429118,597
–4,242687,566727,552
5,000–10,8857,75719,42420,112
1,220,8751,197,1682,073,1792,075,4287,038,2337,224,2808,117,5378,245,730
7,700–35,16535,439
296,451287,761275,691278,203615,007601,4037,502,5307,644,327
23237,462,2547,597,0787,462,2777,597,101
40,25347,2267,502,5307,644,327
1.
Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009 Cayman Islands
2.1
2.2
(a) 1
(b) 8
(c) 12
3.
(a)
322,234217,70255,31528,256377,549245,958
(b)
1,078,6891,020,695
6157551,079,3041,021,450
10%
A102,86387,515B60,72240,038C55,31528,256D43,36327,348
262,263183,157
4.
377,549245,958
(a)
321,466217,071 55,31528,256 768631
377,549245,958 322,234217,702 55,31528,256
377,549245,958 322,234217,702 55,31528,256
377,549245,958
(b)
3090
29,20128,47893,77159,183
–7548,29010,867
131,26599,292
5.
28,25513,08511,87010,1912,6692,15823,70719,40644,91865,751251,066205,358337,322243,773
76,07262,738178,644160,031
6.
16.5%16.5%
2,000,0002,000,0008.25%8.25%
16.5%16. 5%
25%15%
15%15%
50,000,00025%25%50,000,000
30%30%
21%21%
7.
8.
(422,211)(441,343)
1,684,8831,411,655
9.
90,900,00083,996,000
4,00010.
195,431127,95713,938–
(100)(132)
209,269127,825
178,127127,82217,2043195,331127,825
13231
(32)100
–1100132
195,4310.05%100
127,9570.10%132
11.
36,96933,55751,81144,9877,73512,1477,4984,653104,01395,344
12.
1,220,8751,197,168
1,200,564
(3,396)1,197,168
23,7071,220,875
9306.5%
13.
287,76137,693
9,265250,627
(575)(559)
296,451287,76150,000,000325,000,0000.35%
14.
H
AA
A0.000002AB0.000002B
10183,888,050B
1022,200,000B
1068,498,464B
10%10%
0.143329,8330.126137,571
0.17801,1100.17801,920
0.1780(430)0.1780(1,000)
0.1591(8,018)0.0928(4,276)
0.138722,4950.131734,215
1.0472
1.3626
2,7700.0000026-9-18 1-8-291,9000.05516-3-22 15-9-3117,8250.1782-8-20 30-3-3322,495
6,3060.0000026-9-18 15-9-312,4750.05516-3-22 15-9-3125,4340.1782-8-20 27-4-3234,215
(%)66.0442.68-46.53(%)3.64-4.532.19-2.83
1010H1.071.27-1.36
43.1
65.8
A
72A8,948,7500.51%A
A5.49
6.53
1.8
Black-Scholes
(%)30.63-35.68(%)1.97-2.33
2-5A12.28
A
––
6.957,209
6.957,209
7,2096.951515.
139,145130,956
BTKBTK
BTK(1)
(2)BTKBTK
BTK
16.
(a)
12,36611,87417616519,68630,17232,22842,211(b)
*
*(c)
(i)485207485207
(ii)78107
(i)
(ii)
(iii)
(iv)
(d)
5313453134
602117
602117
17.
1,152,00050%50%100%
( www.hkexnews.hk)( www.innocarepharma.com)
19DEL19AD
ALLAMLAQP4 IgG4ARRArriVentArriVent Biopharma ASH
BBBT
BBiogenBiogen Inc.BIIB
BTDBTKBTK
CD20BCD20MS4A1
BCDCCDENMPA
CLLCNSL
9969
DLBCLBDLTEGFREULARFGFRFL
GMP
IBDICP-105ICP-192ICP-022
IL-2-2IL-12-12IL-23-23IMiDIND
IRCITKTITP
JAK
MCDB(DLBCL)
MYD88L265PCD79BMCDMCLBMOA
MSMZLNDAMMOSD
NMPA
NRDLNSCLCNTRK
FGFR(FGFR)TRK
PD
PK
R/Rr/rR-CHOPRICE
264,648,217
SC
0.000002
SHP2RAS
SLESLLSRISLE
T
TTBNKTDCCTTRK
TYK22UC
U.S.
FDAFDA
VivoVivo Opportunity Fund, L.PVivo Capital VIII,
LLCWM